Risk for bleeding-related hospitalizations during use of amiodarone with apixaban or rivaroxaban in patients with atrial fibrillation: a retrospective cohort study
Background: Amiodarone, the most effective antiarrhythmic drug in atrial fibrillation, inhibits
apixaban and rivaroxaban elimination, thus possibly increasing anticoagulant-related risk …
apixaban and rivaroxaban elimination, thus possibly increasing anticoagulant-related risk …
Impact of the Genotype and Phenotype of CYP3A and P-gp on the Apixaban and Rivaroxaban Exposure in a Real-World Setting
Apixaban and rivaroxaban are the two most prescribed direct factor Xa inhibitors. With the
increased use of DOACs in real-world settings, safety and efficacy concerns have emerged …
increased use of DOACs in real-world settings, safety and efficacy concerns have emerged …
Serious Bleeding in Patients With Atrial Fibrillation Using Diltiazem With Apixaban or Rivaroxaban
Importance Diltiazem, a commonly prescribed ventricular rate–control medication for
patients with atrial fibrillation, inhibits apixaban and rivaroxaban elimination, possibly …
patients with atrial fibrillation, inhibits apixaban and rivaroxaban elimination, possibly …
[HTML][HTML] Direct Oral Anticoagulants and Bleeding Management Following Tooth Extractions—A Prospective Cohort Study
R Izzetti, C Cinquini, M Nisi, M Mattiozzi… - Dentistry …, 2024 - pmc.ncbi.nlm.nih.gov
The aim of the present study was to assess the occurrence of intra-, peri-, and post-operative
bleeding following tooth extractions in patients treated with direct oral anticoagulants …
bleeding following tooth extractions in patients treated with direct oral anticoagulants …
Pharmacokinetics and pharmacodynamics of drug‒drug interactions in hospitalized older adults treated with direct oral anticoagulants
T Decaix, K Kemache, P Gay, F Ketz… - Aging Clinical and …, 2024 - Springer
Purpose Polypharmacy is a frequent situation in older adults that increases the risk of drug-
drug interactions (DDIs), both pharmacokinetic (PK) and pharmacodynamic (PD). Direct oral …
drug interactions (DDIs), both pharmacokinetic (PK) and pharmacodynamic (PD). Direct oral …
Risk of Bleeding Among Individuals on Direct-Acting Oral Anticoagulants: An Academic Medical Center Cohort Study
AG Lumbreras, MS Tan, K Moorman-Bishir… - Journal of …, 2022 - journals.lww.com
Previous research has identified risk factors that may affect the risk of bleeding when
individuals are exposed to oral anticoagulants. It is unclear if the risk continues to exist with …
individuals are exposed to oral anticoagulants. It is unclear if the risk continues to exist with …
Разлике у активности фактора коагулационе каскаде и концентрацијама фибриногена и Д-димера, код пацијената са плућном тромбоемболијом на терапији …
J Џудовић - Универзитет одбране, 2023 - nardus.mpn.gov.rs
Терапија директним оралним антикоагулансима (ДОАК) је према савременим
водичима препоручена за лечење пацијената са плућном тромбоемболијом (ПТЕ) …
водичима препоручена за лечење пацијената са плућном тромбоемболијом (ПТЕ) …
[PDF][PDF] UNIVERZITET ODBRANE MINISTARSTVO ODBRANE REPUBLIKE SRBIJE MEDICINSKI FAKULTET VOJNOMEDICINSKE AKADEMIJE
JM Džudović - mfvma.mod.gov.rs
SAŽETAK UVOD: Antikoagulantna terapija direktnim oralnim antikoagulansima (DOAK) je
prema savremenim vodičima apsolutna preporuka za nastavak lečenje pacijenata sa …
prema savremenim vodičima apsolutna preporuka za nastavak lečenje pacijenata sa …